Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, ...

Novo's shares plunged amid rising competition, missed expectations, and governance issues, exposing the risks of neglecting ...

When it was riding high, Novo Nordisk could have done M&A to reduce its dependence on obesity treatments. It didn’t.

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Novo Nordisk A/S understated the impact of lookalike weight-loss injections on its market share before lowering its 2025 ...

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success ...

Unless you’ve been living on another planet over the past few years, you have heard of and probably know several people that ...

Shares of Hims & Hers Health fell 10% in afterhours trading on Monday after the telehealth company reported second-quarter ...

The lawsuits have been filed over the past two weeks in Marion Superior Court against Eli Lilly and Co., which says its drugs ...

Consensus analyst estimates for Novo Nordisk (NVO) earnings per share and revenue land at $0.92 and $11.9 billion, ...

Ali Eastburn, from Nashville in Tennessee , US, who was a size 16, was prescribed the drug by her doctor in April to feel ...